FDA’s New Guidance for Industry Addressing Evaluation of the Safety of New Drugs for Improving Glycemic Control: A Case Study in Regulatory Science

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text

Medicine, Endocrinology, Pharmacotherapy +13

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald et al. · New England Journal of Medicine · 2013 · 3.5K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong et al. · New England Journal of Medicine · 2015 · 2.6K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

William B. White, Christopher P. Cannon, Simon Heller et al. · New England Journal of Medicine · 2013 · 2.5K citations · Full text

Medicine, Cardiology, Internal Medicine +14